Tango Therapeutics
Develops MTAP-selective PRMT5 inhibitors for genetically defined cancers.
$23.49
After-hours close+0.13 (+0.56%)
At close$23.36(−7.59%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 133.97%Insiders 1.56%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 162.81M · Float 106.26M · 65.3% free float
Institutions13F, as of Jun 30, 2026
257 holders · 218.13M shares · 80 new positions · 181 increased · 56 reduced · 25 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| RTW Investments, LP | 13.90M | 8.54% | +600.0K | Aug 14, 2026 |
| BlackRock, Inc. | 12.44M | 7.64% | +3.69M | Aug 7, 2026 |
| FMR LLC | 12.33M | 7.58% | +2.43M | Aug 13, 2026 |
| Farallon Capital Management LLC | 12.28M | 7.54% | +3.18M | Aug 14, 2026 |
| Boxer Capital Management, LLC | 10.88M | 6.68% | 0 | Aug 14, 2026 |
| Goldman Sachs Group Inc | 9.98M | 6.13% | +4.90M | Aug 14, 2026 |
| TCG Crossover Management, LLC | 9.08M | 5.58% | −1.45M | Aug 14, 2026 |
| TRV GP Iv, LLC | 6.37M | 3.92% | 0 | Aug 10, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Davis Aaron I.incl. BCTG Holdings, LLC, MVA Investors, LLC +1 more | 10.00% | 10.74M | 13D | Jan 2, 2025 ↗ |
| TCG Crossover GP II, L.P. | 9.99% | 13.52M | 13G | Feb 17, 2026 ↗ |
| RTW Investments, LP | 9.30% | 13.30M | 13G | May 15, 2026 ↗ |
| Adage Capital Management, L.P. | 8.98% | 12.81M | 13G | May 13, 2026 ↗ |
| TCG Crossover GP II, LLC | 8.10% | 11.60M | 13G | May 15, 2026 ↗ |
| FMR LLC | 6.90% | 9.91M | 13G | May 6, 2026 ↗ |
| BlackRock, Inc. | 6.30% | 8.48M | 13G | Jan 21, 2026 ↗ |
| The Goldman Sachs Group, Inc. | 6.00% | 9.74M | 13G | Aug 14, 2026 ↗ |
| Woodline Partners LP | 5.60% | 8.00M | 13G | May 15, 2026 ↗ |
| Nextech Crossover I GP S.a. r.l. | 5.10% | 7.27M | 13G | May 15, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Third Rock Ventures IV, L.P. | 10 percent owner | 13.39M | 8.22% | Oct 27, 2025 |
| Barbara Weber | director, officer: Director, Executive Chair | 1.63M | 1.00% | Feb 4, 2026 |
| Malte Peters | director, officer: President & CEO | 367.5K | 0.23% | Jan 12, 2026 |
| Daniella Beckman | officer: Chief Financial Officer | 184.3K | 0.11% | Feb 4, 2026 |
| Adam Crystal | officer: President, R&D | 115.7K | 0.07% | Aug 5, 2026 |
| Jessica Newcomb | officer: Principal Accounting Officer | 67.3K | 0.04% | Apr 24, 2026 |
| Mace Rothenberg | director | 41.5K | 0.03% | Jun 8, 2026 |
| Matthew Gall | officer: Chief Financial Officer | 40.0K | 0.02% | May 5, 2026 |
| John B. Ketchum | director | 24.9K | 0.02% | Jun 8, 2026 |
| Sung Lee | director | 22.9K | 0.01% | Jun 8, 2026 |
4 ten-percent owners hold 31.03M shares by Form 4, outside the officers-and-directors figure above · 12 people have not refiled in the last 18 months (26.22M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 3, 2026 | Adam Crystalofficer: President, R&D | Sale · 2 lots | 27,000 | $27.24 | 115,743 |
| Jul 1, 2026 | Adam Crystalofficer: President, R&D | Sale · 2 lots | 27,000 | $29.59 | 115,743 |
| Jun 1, 2026 | Adam Crystalofficer: President, R&D | Sale · 2 lots | 27,000 | $22.87 | 115,743 |
| May 1, 2026 | Adam Crystalofficer: President, R&D | Sale · 2 lots | 27,000 | $21.23 | 115,743 |
| Apr 15, 2026 | Adam Crystalofficer: President, R&D | Sale | 38,460 | $25.00 | 112,622 |
| Apr 1, 2026 | Adam Crystalofficer: President, R&D | Sale | 27,000 | $21.20 | 112,622 |
| Mar 25, 2026 | Adam Crystalofficer: President, R&D | Sale | 12,000 | $20.11 | 112,622 |
| Mar 5, 2026 | Adam Crystalofficer: President, R&D | Sale | 20,251 | $15.00 | 112,622 |
| Feb 25, 2026 | Adam Crystalofficer: President, R&D | Sale | 54,345 | $12.77 | 132,873 |
| Feb 3, 2026 | Adam Crystalofficer: President, R&D | Sale · 2 lots | 18,452 | $12.26 | 187,218 |
CongressHouse and Senate disclosures
Not reported.